September 25, 2021. Monoclonal Antibodies May Reduce Hospitalizations in High Risk Ambulatory Patients with COVID-19


This article (this article is a preprint and has not been peer reviewed yet) shows a quasi-experimental observational cohort study using target trial emulation and causal inference methodology in pre-and post-implementation groups, comparing a cohort that received a monoclonal antibody infusion with a cohort that did not receive them. The inclusion criteria was to have ambulatory, high risk for hospitalization COVID-19.

This study, showed a statistically significant difference in the rates of hospitalization between the cohort that received the monoclonal antibodies and the ones that did not. The difference was about 18% hospitalization versus about 12%

This study shows that the best use of monoclonal antibodies may be used to reduce hospitalization due to COVID-19.

Any information or statement present in this post does not replace your health care provider’s advice or treatment. This blog does not provide medical advice, prescribe medications or therapies, or diagnose conditions, it only expresses an opinion. If you have a health-related question or condition, confer with your healthcare provider.